- Stocks
- Healthcare
- NASDAQ: ALT

Price (delayed)

$15.98

Market cap

$613.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$463.61M

ALT's quick ratio is up by 28% QoQ

The equity has increased by 9% since the previous quarter

ALT's revenue is up by 35% year-on-year but it is down by 17% since the previous quarter

The gross profit has grown by 35% YoY but it has contracted by 17% from the previous quarter

Altimmune's net income has shrunk by 169% YoY and by 22% QoQ

Altimmune's EPS has decreased by 34% YoY and by 6% QoQ

What are the main financial stats of ALT

Market
Valuations
Earnings

Shares outstanding

38.4M

Market cap

$613.58M

Enterprise value

$463.61M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.41

Price to sales (P/S)

91.32

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

68.08

Revenue

$6.81M

EBIT

-$62.17M

EBITDA

-$61.88M

Free cash flow

-$54.05M

Per share
Balance sheet
Liquidity

EPS

-$2.03

Free cash flow per share

-$1.39

Book value per share

$6.63

Revenue per share

$0.17

TBVPS

$6.46

Total assets

$264.25M

Total liabilities

$17.81M

Debt

$0

Equity

$246.44M

Working capital

$235.37M

Debt to equity

0

Current ratio

24.96

Quick ratio

23.55

Net debt/EBITDA

2.42

Margins
Efficiency
Dividend

EBITDA margin

-908.6%

Gross margin

100%

Net margin

-881.4%

Operating margin

-915.6%

Return on assets

-28.4%

Return on equity

-31.9%

Return on invested capital

-86.7%

Return on capital employed

-24.4%

Return on sales

-913%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Altimmune stock price performed over time

Intraday

0.76%

1 week

11.2%

1 month

13.57%

1 year

118.9%

YTD

41.67%

QTD

13.09%

How have Altimmune's revenue and profit performed over time

Revenue

$6.81M

Gross profit

$6.81M

Operating income

-$62.35M

Net income

-$60.02M

Gross margin

100%

Net margin

-881.4%

Altimmune's net income has shrunk by 169% YoY and by 22% QoQ

Altimmune's operating income has plunged by 136% YoY and by 14% from the previous quarter

The net margin has dropped by 100% year-on-year and by 47% since the previous quarter

The operating margin has dropped by 75% year-on-year and by 37% since the previous quarter

What is Altimmune's growth rate over time

What is Altimmune stock price valuation

P/E

N/A

P/B

2.41

P/S

91.32

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

68.08

Altimmune's EPS has decreased by 34% YoY and by 6% QoQ

The P/B is 51% higher than the 5-year quarterly average of 1.6 and 21% higher than the last 4 quarters average of 2.0

The equity has increased by 9% since the previous quarter

ALT's P/S is 59% above its last 4 quarters average of 57.5

ALT's revenue is up by 35% year-on-year but it is down by 17% since the previous quarter

How efficient is Altimmune business performance

Altimmune's return on sales has shrunk by 80% YoY and by 37% QoQ

The return on equity rose by 31% year-on-year and by 11% since the previous quarter

ALT's ROA is up by 28% YoY and by 8% QoQ

The company's return on invested capital rose by 27% YoY and by 13% QoQ

What is ALT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALT.

How did Altimmune financials performed over time

The total liabilities is up by 44% year-on-year but it has declined by 7% since the previous quarter

Altimmune's current ratio has increased by 30% from the previous quarter

The debt is 100% smaller than the equity

The equity has increased by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.